PharmaShots | Incisive News in 3 Shots

Subscribe Now

coronary artery disease

AstraZeneca Reports Results of Brilinta (ticagrelor) in P-III THEMIS Study for Coronary Artery Disease and Type-2 Diabetes

AstraZeneca Reports Results of Brilinta (ticagrelor) in P-III THEMIS Study for Coronary Artery Disease and Type-2 Diabetes

September 2, 2019

Bayer's Gadavist (gadobutrol) Injection Receives the US FDA's Approval for use in CMRI in Patients with Coronary Artery Disease

Bayer's Gadavist (gadobutrol) Injection Receives the US FDA's Approval for use in CMRI in Patients with Coronary Artery Disease

July 16, 2019

AstraZeneca Reports Results of Brilinta (ticagrelor) in P-III THEMIS Trial for Patients with Coronary Artery Disease (CAD) and Type-2 Diabetes (T2D)

AstraZeneca Reports Results of Brilinta (ticagrelor) in P-III THEMIS Trial for Patients with Coronary Artery Disease (CAD) and Typ...

February 25, 2019

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us